Clinical trials recruiting in Fairfax, Virginia

Phase breakdown

Conditions recruiting in Fairfax, Virginia

Recruiting trials in Fairfax, Virginia

• A 2-part Phase 1/2 Open-label Trial on ODM-212
  NCT07563738 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
  NCT05753722 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
  NCT07584226 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female)
• A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
  NCT06905197 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
  NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
  NCT07458347 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
  NCT05948865 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
  NCT07317505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
  NCT07491497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
  NCT06785636 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
  NCT07644559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
  NCT07365995 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
  NCT06992258 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
  NCT07365319 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  NCT07217171 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
  NCT07029399 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT07719361 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ASP1002 in Adults for Treatment of Solid Tumors
  NCT05719558 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
  NCT07287995 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
  NCT07730021 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
  NCT06095505 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
  NCT06765668 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of DM005 in Patients With Advanced Solid Tumors
  NCT06515990 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female)
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  NCT06983743 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer
  NCT07524855 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
  NCT07174583 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  NCT07221474 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
  NCT07107230 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
  NCT05456256 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
  NCT07383506 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
  NCT06907043 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female)
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PHN-012 in Patients With Advanced Solid Tumors
  NCT07127874 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  NCT07300150 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  NCT03093116 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female)
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
  NCT06385925 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Showing 100 of 266 recruiting trials.

Common questions

How many clinical trials are recruiting in Fairfax, Virginia?

266 recruiting trials have at least one study site in Fairfax, Virginia.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.